Tag Archives: NASDAQ:GGAL

Analysts’ Perspective: Celsion (CLSN), Grupo Financiero Galicia (GGAL), Lennar (LEN)

Celsion Corp. (NASDAQ:CLSN) shares were upgraded by analysts at Maxim Group from Hold to Buy rating with a price target of $7.

Celsion Corp. is an oncology drug development company. It focuses on developing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA- based therapies.

*

Brokerage Firm UBS upgraded Grupo Financiero Galicia S.A. (NASDAQ:GGAL) shares from Neutral to Buy rating.

Grupo Financiero Galicia SA is a holding company, which engages in banking, insurance, and the issuance of certificates of deposit through its subsidiaries.

*

Investment Analysts at MKM Partners upgraded Lennar Corp. (NYSE:LEN) shares from Neutral to Buy rating.

Lennar Corp. engages in the provision of real estate related financial services and investment management.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/